Chan Yoon Cheah
Professor, Consultant Haematologist
Sir Charles Gairdner Hospital / University of Western Australia · Perth, Australia
Australian MCL expert with significant contributions to BTK inhibitor research and novel agent clinical trials for MCL.
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.
The Lancet. Haematology · May 1, 2026
Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion.
Leukemia & lymphoma · Mar 17, 2026
Approaches to the management of relapsed/refractory mantle cell lymphoma: navigating an increasingly complex therapeutic landscape.
Expert review of hematology · Mar 1, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.
Current medical research and opinion · Dec 1, 2025
EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma.
HemaSphere · Oct 1, 2025
Recent advances and future directions in newly diagnosed mantle cell lymphoma.
Expert opinion on pharmacotherapy · Sep 1, 2025
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 10, 2025
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 10, 2025
"The End of the Golden Weather": therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors.
Haematologica · Mar 1, 2025
Diagnosis and management of mantle cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.
Internal medicine journal · Jan 1, 2025
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Haematologica · Jan 1, 2025
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia.
Nature reviews. Clinical oncology · Dec 1, 2024
CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.
Blood · Feb 22, 2024
Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom.
British journal of haematology · Feb 1, 2024